Fosphenytoin vs Rufinamide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Epilepsy

Shared mechanism: Voltage-gated sodium channel · full Epilepsy pipeline

Fosphenytoin

Marketed by Pfizer

Approved in Epilepsysmall molecule
Partial signal

NCT01960075 · Phase 3 · completed

This randomized, triple-blind phase 3 trial (ESETT) compared intravenous fosphenytoin, valproic acid and levetiracetam in 478 enrolments with benzodiazepine-refractory status epilepticus. The primary endpoint was clinical cessation of status epilepticus within 60 minutes. The trial stopped early for futility under a prespecified rule; in the intention-to-treat analysis of the first 400 patients, seizures stopped in 53 of 118 participants on fosphenytoin, 56 of 121 on valproic acid and 68 of 145 on levetiracetam, and no arm was shown to be superior.

No aligned efficacy figure on record for this race.

Rufinamide

Marketed by Eisai and partners

Approved in Epilepsysmall molecule
Partial signal

NCT00334958 · Phase 3 · completed

This randomized, double-blind, placebo-controlled Phase 3 study gave adjunctive rufinamide 3,200 mg/day or placebo to adolescents and adults with refractory partial-onset seizures (357 randomized). Its single registered primary endpoint was the percentage change in total partial seizure frequency per 28 days. The median reduction was 23.25% with rufinamide and 9.80% with placebo, and the peer-reviewed paper reports p = 0.007, so the primary endpoint was met. The registry posts the same medians but no statistical test; the p-value comes from Biton et al., Epilepsia 2011.

The p-value comes from the peer-reviewed paper (Biton et al., Epilepsia 2011); ClinicalTrials.gov posts the medians with no statistical analysis.

Reported efficacy

Percentage Change in Total Partial Seizure Frequency Per 28 Days During Maintenance Phase Relative to the Baseline Phase (Baseline, Days 13 to 96): Primary endpoint, median percentage reduction in total partial seizure frequency per 28 days (maintenance phase vs baseline, ITT): rufinamide 23.25% vs placebo 9.80%, p = 0.007 (Biton et al., Epilepsia 2011; CT.gov posts the same medians with no statistical analysis). (met)

Result source: NCT00334958

Results for Epilepsy

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointFosphenytoinRufinamide
Seizure frequency, % change—Not posted · NCT00908453—Not reported
50% responder rate—Not posted · NCT00908453—Not reported
Seizure freedom—Not posted · NCT00908453—Not reported

Seizure frequency, % change

Fosphenytoin
—Not posted · NCT00908453
Rufinamide
—Not reported

50% responder rate

Fosphenytoin
—Not posted · NCT00908453
Rufinamide
—Not reported

Seizure freedom

Fosphenytoin
—Not posted · NCT00908453
Rufinamide
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Fosphenytoin: 3 of 4 rows · Rufinamide: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricFosphenytoinRufinamide
Dropout rate
38.2%a
NCT00510783 · Phase 4 · registry result, not featured evidence
show 1 more result
—400mg
NCT01458522 · Phase 2 · registry result, not featured evidence
21%b
NCT00334958 · Phase 3 · monotherapy · Epilepsy · phase 3
show 3 more results
13.8%
NCT01146951 · Phase 3 · monotherapy
40%
NCT01405053 · Phase 3 · add on · Epilepsy, Lennox-Gastaut Syndrome · phase 3
24.1%
NCT01151540 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
—a
NCT00510783 · Phase 4 · registry result, not featured evidence
show 1 more result
—400mg
NCT01458522 · Phase 2 · registry result, not featured evidence
15.3%b
NCT00334958 · Phase 3 · monotherapy · Epilepsy · phase 3
show 3 more results
13.8%
NCT01146951 · Phase 3 · monotherapy
12%
NCT01405053 · Phase 3 · add on · Epilepsy, Lennox-Gastaut Syndrome · phase 3
7.4%
NCT01151540 · Phase 3 · registry result, not featured evidence
Serious AEs
0%a
NCT00510783 · Phase 4 · registry result, not featured evidence
show 1 more result
22.2%400mg
NCT01458522 · Phase 2 · registry result, not featured evidence
3.4%b
NCT00334958 · Phase 3 · monotherapy · Epilepsy · phase 3
show 3 more results
3.4%
NCT01146951 · Phase 3 · monotherapy
40%
NCT01405053 · Phase 3 · add on · Epilepsy, Lennox-Gastaut Syndrome · phase 3
16.7%
NCT01151540 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
a
dizziness 9.2%
fatigue 9.2%
burning at the iv site 6.6%
NCT00510783 · Phase 4 · registry result, not featured evidence
show 1 more result
400mg
respiratory failure 6.7%
acute respiratory failure 4.4%
bradycardia 4.4%
NCT01458522 · Phase 2 · registry result, not featured evidence
b
dizziness 26.7% (placebo 8.3%)
headache 16.5% (placebo 12.8%)
fatigue 15.3% (placebo 10%)
NCT00334958 · Phase 3 · monotherapy · Epilepsy · phase 3
show 3 more results
nasopharyngitis 31% (placebo 30%)
status epilepticus 27.6% (placebo 16.7%)
decreased appetite 20.7% (placebo 6.7%)
NCT01146951 · Phase 3 · monotherapy
upper respiratory tract infection 28%
vomiting 28%
somnolence 20%
NCT01405053 · Phase 3 · add on · Epilepsy, Lennox-Gastaut Syndrome · phase 3
nasopharyngitis 48.1%
status epilepticus 40.7%
somnolence 25.9%
NCT01151540 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.
  2. bPopulation comparability has not been reviewed for 2 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Fosphenytoin

Seizure Recurrence 24 h 3.9% (n=76) vs 2.4% (n=82) Phenytoin/Fosphenytoin @ 0.142857wk
event count · % of participants
NCT00510783 · Phase 4 · registry result, not featured evidence · converted to % from 3 participants as posted
Seizure-free 54.3% (n=35) vs 62.9% (n=35) fPHT @ 0.14wk400mg
event count · % of participants
NCT01458522 · Phase 2 · registry result, not featured evidence · converted to % from 19 Participants as posted
Seizure Burden -0.58 vs -0.54 fPHT per hour @ 0.14wk400mg
absolute change · per hour
NCT01458522 · Phase 2 · registry result, not featured evidence

Rufinamide

Seizure Frequency 50 32.5% (n=160) vs 14.3% (n=175) placebo @ 14wk
responder rate · % of participants
Maintenance
NCT00334958 · Phase 3 · monotherapy · Epilepsy · phase 3
Tonic-atonic Seizure 50% Reduction 25% (n=28) vs 6.7% (n=30) placebo @ 12wk
event count · % of participants
Yes (50% Reduction Achieved)
NCT01146951 · Phase 3 · monotherapy · converted to % from 7 Participants as posted
Drop Seizure Frequency -39.3% (n=46) @ 12wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 12
NCT01151540 · Phase 3 · registry result, not featured evidence
Drop Seizure Frequency -40.6% (n=46) @ 24wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 24
NCT01151540 · Phase 3 · registry result, not featured evidence
Drop Seizure Frequency -46.8% (n=46) @ 32wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 32
NCT01151540 · Phase 3 · registry result, not featured evidence
Drop Seizure Frequency -47.6% (n=46) @ 40wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 40
NCT01151540 · Phase 3 · registry result, not featured evidence
Drop Seizure Frequency -36.05% (n=46) @ 52wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 52
NCT01151540 · Phase 3 · registry result, not featured evidence
Seizure Frequency -47.7% (n=46) @ 12wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 12
NCT01151540 · Phase 3 · registry result, not featured evidence
Seizure Frequency -48.9% (n=46) @ 24wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 24
NCT01151540 · Phase 3 · registry result, not featured evidence
Seizure Frequency -50.6% (n=46) @ 32wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 32
NCT01151540 · Phase 3 · registry result, not featured evidence
Seizure Frequency -52% (n=46) @ 40wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 40
NCT01151540 · Phase 3 · registry result, not featured evidence
Seizure Frequency -47.35% (n=46) @ 52wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Percent Change in Week 52
NCT01151540 · Phase 3 · registry result, not featured evidence

+ 5 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Fosphenytoin's landscape · Rufinamide's landscape